Ocular Therapeutix Inc
$ 8.47
3.80%
09 Jun - close price
- Market Cap 1,786,716,000 USD
- Current Price $ 8.47
- High / Low $ 8.51 / 8.07
- Stock P/E N/A
- Book Value 3.03
- EPS -1.44
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.69 %
- 52 Week High 16.44
- 52 Week Low 6.23
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$26.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-05 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-14 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.4 | -0.29 | -0.38 | -0.39 | -0.38 | -0.29 | -0.22 | -0.26 | -0.24 | -0.35 | -0.19 | -0.26 |
| Estimated EPS | -0.31 | -0.34 | -0.35 | -0.35 | -0.29 | -0.22 | -0.21 | -0.21 | -0.18 | -0.3 | -0.25 | -0.29 |
| Surprise | -0.09 | 0.05 | -0.03 | -0.04 | -0.09 | -0.07 | -0.01 | -0.05 | -0.06 | -0.05 | 0.06 | 0.03 |
| Surprise Percentage | -29.0323% | 14.7059% | -8.5714% | -11.4286% | -31.0345% | -31.8182% | -4.7619% | -23.8095% | -33.3333% | -16.6667% | 24% | 10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2026-06-08 06:39:25
Ocular Therapeutix (OCUL) has experienced recent share price weakness, with its stock down 6.3% on the day and further declines over the past week, month, and three months. Despite this, the company is valued at a large discount to a US$26 price target, primarily driven by the potential approval of AXPAXLI for wet AMD, which could significantly boost its market share and revenue. However, another perspective cautions that the stock's current high Price-to-Sales ratio (34.7x) compared to industry averages raises concerns about whether future growth can justify such a premium.
2026-06-06 06:39:25
Nadia Waheed, CMO of Ocular Therapeutix (NASDAQ:OCUL), sold 14,828 shares worth approximately $122,627. This "sell-to-cover" transaction was to satisfy tax obligations related to restricted stock units and not a discretionary trade. Despite the sale, Waheed still directly owns 300,079 shares, and the company is deemed undervalued by InvestingPro analysis, with price targets ranging from $18 to $34.
2026-06-06 06:39:25
Ocular Therapeutix, Inc. announced that it granted inducement awards to seven new non-executive employees under its 2019 Inducement Stock Incentive Plan. These awards, consisting of stock options and restricted stock units for an aggregate of 51,775 and 16,950 shares respectively, were provided as an inducement for their employment. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4), with specific vesting schedules tied to continued service.
2026-06-05 20:09:49
Ocular Therapeutix, Inc.'s Chief Medical Officer, Nadia Waheed, automatically sold 14,828 shares of common stock at a weighted average price of $8.27 per share. This sale was a pre-established transaction to cover tax withholding obligations associated with restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following the transaction, Waheed directly holds 300,079 shares of common stock.
2026-06-05 20:09:49
Nadia Waheed, CMO of Ocular Therapeutix (NASDAQ:OCUL), sold 14,828 shares worth approximately $122,627 on June 3, 2026. This "sell-to-cover" transaction was to satisfy tax obligations from vested restricted stock units and not a discretionary trade. Despite recent earnings falling short of expectations, InvestingPro analysis indicates the stock may be undervalued with analyst price targets ranging from $18 to $34.
2026-06-05 17:38:50
Ocular Therapeutix, Inc. announced inducement grants to seven new non-executive employees, consisting of stock options and restricted stock units. These awards, made under the company's 2019 Inducement Stock Incentive Plan, are detailed with their vesting schedules and exercise prices. The company continues to advance its product pipeline, including AXPAXLI for retinal diseases and DEXTENZA for ocular inflammation.
